Your body's metabolic response to semaglutide depends on the dose and your individual GLP-1 receptor sensitivity, not on stomach contents at the moment of injection
By enhancing the depth of SWS, they could be particularly beneficial for individuals whose sleep cycles are disrupted by stress, aging, or underlying conditions
[3] Patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 should not use tirzepatide, and any symptoms such as neck mass, hoarseness, difficulty swallowing, or shortness of breath should be reported immediately
pancreatitis) have been reported [11], and some people who use GLP-1 medications experience malnutrition [20,21,22,23], further raising safety considerations
Dec 2025;89:102049